Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod in Huntington's Disease
NCT02215616Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of laquinimod in Huntington's disease (HD), sponsored by Teva Pharmaceutical Industries Ltd.. Started Oct 2014; status: completed.
02
Drugs
laquinimod
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02215616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215616.